Performance of Co-Development. The JRDC shall supervise Co-Development with the goal of achieving Regulatory Approval of such Development Compound as quickly as possible. In all countries and territories [ * ], Miles shall have the primary responsibility for performing the required tasks of Co-Development pursuant to the world-wide Co-Development Plan, including conducting all clinical trials and obtaining all Regulatory Approvals necessary for marketing Collaboration Products. Onyx shall assist Miles at Miles’ reasonable request in performing such Co-Development tasks; provided, however, that Miles shall at all times have decision-making authority and remain ultimately responsible for completion of all such tasks and obligations. Miles’ (and Onyx’, where appropriate) performance of such Co-Development obligations shall be under the management and supervision of the JRDC, and each Party shall keep the JRDC informed as to all significant work in Clinical Development Period hereunder. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. [ * ] Miles and Onyx shall jointly participate in performing Co-Development tasks with equal participation by the Parties to the extent practical, under the supervision of the JRDC. Subject to the principle of equal participation, the Parties expect that such Co-Development will rely, to the extent it is economically indicated, on the existing structure and capabilities of Miles for performing Clinical Development Period tasks. Promptly after selection of a Collaboration Compound for Co-Development, the Parties shall meet to define a specific mechanism for such joint Co-Development [ * ].
